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Total body computed tomography (TB-CT) scan is not mandatory in the diagnostic/staging algorithm of
chronic lymphocytic leukemia (CLL). The aim of this study was to determine the value and prognostic signifi-
cance of TB-CT scan in early stage CLL patients. Baseline TB-CT scan was performed in 240 Binet stage A
CLL patients (179 Rai low- and 61 Rai intermediate-risk) included in a prospective multicenter observational
study (clinicaltrial.gov ID:NCT00917549). The cohort included 69 clinical monoclonal B lymphocytosis
(cMBLs). Patients were restaged considering only radiological data. Following TB-CT scans, 20% of cases
reclassified as radiologic Binet (r-Binet) stage B. r-Binet B patients showed a higher incidence of unfavorable
cytogenetic abnormalities (P5 0.027), as well as a shorter PFS (P5 0.001). At multivariate analysis, r-Binet
stage [HR5 2.48; P50.004] and IGHV mutational status [HR53.01; P5 0.002] retained an independent pre-
dictive value for PFS. Among 179 Rai low-risk cases, 100 were redefined as r-Rai intermediate-risk based
upon TB-CT scan data, showing a higher rate of cases with higher ZAP-70 (P5 0.033) and CD38 expression
(P5 0.029) and b2-microglobulin levels (P<0.0001), as well as a shorter PFS than those with r-Rai low-risk
(P5 0.008). r-Rai stage [HR5 2.78; P5 0.046] and IGHV mutational status [HR5 4.25; P5 0.009] retained a sig-
nificant predictive value for PFS at multivariate analysis. Forty-two percent of cMBL patients were reclassified
as r-small lymphocytic lymphomas (r-SLLs) by TB-CT scan. TB-CT scan appears to provide relevant informa-
tion in early stage CLL related to the potential and the timing of patients to progress towards the more
advanced disease stages. Am. J. Hematol. 88:539–544, 2013. VC 2013 Wiley Periodicals, Inc.
Introduction
Chronic lymphocytic leukemia (CLL) patients show a vari-
able clinical course with some cases having an almost nor-
mal progression-free life span and others require therapy
shortly after diagnosis [1]. Rai et al. and Binet et al. staging
systems, which consider the extent of lymphadenopathy,
organomegaly, and cytopenias, are useful for assessing
prognosis [2,3]. However, for early stage patients it is virtu-
ally impossible to predict the clinical course. The use of se-
rum indicators, i.e., b2-microglobulin [4] and free-light
chains [5], along with molecular and cytogenetic markers
[6] may provide valuable information, although most of
these markers are not routinely employed in clinical
practice.
Additional Supporting Information may be found in the online version of this article.
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Research Article
The current staging systems are based on clinical exami-
nation and blood counts, an approach maintained by the
National Cancer Institute CLL Working Group (NCI/WG)
guidelines, which do not recommend computed tomography
(CT) scan at diagnosis [7,8]. For this reason, abdominal
and thoracic lymphadenopathies are not incorporated in
the staging procedures. Moreover, certain liver or spleen
enlargements may go undetected at clinical examination
and hence not be computed into the staging determination.
This is in contrast with the staging procedure of nearly all
other lymphoid malignancies, where CT and often PET
scans are highly recommended or mandatory [9,10]. None-
theless, Muntanola et al. have shown that among Rai 0
patients abdominal lymphadenopathy or splenomegaly
detected by CT scan predict disease progression [11]. De-
spite this, there have been no further studies addressing
the issue systematically.
In the present study, we investigated the value of TB-CT
scans in a cohort of Binet A patients participating in a
prospective multicenter observational study. Subanalyses
have also been performed in the setting of Rai low-risk and
of cMBL cases, included in this cohort given the particular
study design.
Methods
Patients
Newly diagnosed CLL patients from several Italian Institutions were
prospectively enrolled into the O-CLL1-GISL protocol (clinicaltrial.gov
identifier: NCT00917540). The inclusion criteria for CLL diagnosis,
employed at the time of study start, followed the NCI/WG guidelines
established in 1996 requiring >5.000 lymphocytes/microliter in the pe-
ripheral blood [7]. Exclusion criteria were the following: (i) diagnosis
>12 months before registration; (ii) CD52 and/or CD232 B-lymphoproli-
ferative disorders; (iii) clinical Binet stage B or C; (iv) need of therapy
according to NCI/WG guidelines; and (v) age >70 years. CLL cell phe-
notype, CD38 and ZAP-70 expression, and IGHV mutational status
was centralized at the laboratory in Genoa, while cytogenetic analyses
in Milan. All patients underwent bone marrow biopsy at baseline. This
study was approved by the ethics committees of the participating cen-
ters. All patients provided written informed consent.
To date, of 463 Binet stage A patients enrolled 240 (179 Rai low-
and 61 Rai intermediate-risk) [12] underwent TB-CT scan at baseline
and were included in this study (Fig. 1). Our series is representative of
all 463 cases, since there is a similar distribution of clinical and biologi-
cal parameters in the two subgroups (Supporting Information Table I).
Sixty-nine of the 240 cases satisfied the 2008 NCI/WG criteria for the
definition of cMBL (<5.0 3 109 B lymphocytes/L in the peripheral blood
and no apparent lymph node, spleen, or liver enlargement) [8].
All patients underwent follow-up visit every 6 months until progres-
sion defined as need for therapy according to NCI/WG guidelines [8]. A
minimum follow-up of 6 months was available for 230/240 cases and
were evaluated for progression-free survival (PFS).
Assessment of biological markers
Cytogenetic abnormalities involving deletions at chromosomes
11q23, 13q14, and 17p13 and trisomy 12 were evaluated by FISH in
purified CD191 population as previously described [5]. Cytogenetic
abnormalities were clustered in that risk groups [i.e., low- (del(13q14)
and normal), intermediate- (trisomy 12), and high-risk [del(11q22) and
del(17p13)]. CD38-positive leukemic cells were measured by triple
staining with CD19-FITC (BD Biosciences), CD38-PE (BD Bioscien-
ces), and CD5-PC5 (Beckman Coulter). The cells were analyzed using
a FACSCalibur flow-cytometer (BD Biosciences). CD38-positive cases
were indicated as those having greater than 30% positive cells. ZAP-
70 was determined by flow-cytometry with a ZAP-70-FITC (clone
2F3.2, Millipore) or an isotype control mAb (mouse IgG2a-FITC BD
Biosciences) as previously described [6]. ROC curve analysis identified
40% of ZAP-70-positive cells as the best cut-off value for distinguishing
IGHV unmutated (IGHV-UM) from IGHV mutated (IGHV-M) cases
(AUC5 0.64, P5 0.002). Therefore, 40% was used as threshold to
identify ZAP-70-positive cases. IGHV mutational status was assessed
on cDNA specimens [13]. Sequences were aligned to the IMGT direc-
tory and analyzed using IMGT/VQUEST software. Sequences differing
more than 2% from the corresponding germ-line gene were considered
IGHV-M [13].
Integration of TB-CT scans in the Binet and Rai staging systems
CT scans of the head-neck, chest, abdomen, and pelvis were per-
formed in craniocaudal direction, with a 5- to 8-mm collimation. The
scans were routinely acquired 70 s after the injection of 100–200 ml of
iodinated contrast material, at a rate of 3 ml/s by powered injection.
Radiologists evaluated TB-CT scans according to the following
shared criteria. The assessment of nodal groups status was based on
size [14], the maximum short-axis diameter of lymph nodes was taken
as the most reliable parameter to determine lymph node size according
to standard criteria [15]. Lymph nodes >10 mm in diameter were con-
sidered abnormal according to the Binet staging system.3. Furthermore,
lymph nodes were also considered abnormal if multiple nodes meas-
uring <10 mm in the short-axis diameter were seen in a single region
[16]. Splenomegaly and hepatomegaly were defined based upon the
changes that an enlarged spleen and liver caused in relation to the
other abdominal viscera; liver and spleen volume were calculated
according to standard diagnostic criteria [17]. The normal volume for
the spleen was <375 cm3 for males and <309.55 cm3 for females, for
the liver <2275.47 cm3 for males and <1927.46 cm3 for females [17].
Based only on TB-CT scan data, all patients were reclassified
Figure 1. CONSORT diagram of the study. The diagram shows the distribution of CLL cases enrolled in the study according to execution of TB-CT scans and to clini-
cal and radiological staging systems. Int: intermediate; r: radiological.
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according to Binet classification and assigned to radiologic Binet (r-
Binet) A (patients with <3 areas of nodal or organ enlargement) or r-
Binet B (patients with >3 areas of nodal or organ enlargement). In this
modified restaging, we considered as areas of involvement: (1) head
and neck lymph nodes (including Waldeyer’s ring) (uni-/bilateral), (2)
axillary lymph nodes (uni-/bilateral), (3) inguinal lymph nodes (uni-/bilat-
eral), (4) thoracic lymph nodes (uni-/bilateral), (5) abdominal lymph
nodes (uni-/bilateral), (6) splenomegaly, (7) hepatomegaly. Likewise,
179 clinical Rai low-risk patients within this cohort were reclassified as
r-Rai low-risk (patients without lymphadenopathies and organomegaly)
and r-Rai intermediate-risk groups (patients with lymphadenopathies at
any site, and/or splenomegaly and/or hepatomegaly). Finally, 69 cMBL
patients were divided into r-cMBL and r-SLL cases. Since, for SLL
cases the staging should be carried out according to lymphoma guide-
lines, only cases with lymph nodes >15 mm in diameter and/or spleno-
megaly were considered as r-SLL [18,19].
Statistical analysis
SPSS for Windows, v13.0, 2004 software (SPSS, UK) was used for
all analyses. For categorical variables, statistical comparisons were
performed using two-way tables for the Fisher’s exact test and multi-
way tables for the Pearson’s Chi-square test. PFS analyses were per-
formed using the Kaplan–Meier method in patients with a minimum 6
month follow-up. Statistical significance of associations between indi-
vidual variables and survival was calculated using the log-rank test.
Prognostic impact for the outcome variable was investigated by univari-
ate and multiple Cox regression analysis. Data are expressed as haz-
ard ratio (HR) and 95% confidence interval (CI). A value of P< 0.05
was considered significant.
Results
Clinical versus radiologic staging
This cohort included 240 Binet A patients (179 Rai low-
and 61 Rai intermediate-risk). Of these, 69 met the diag-
nostic criteria of cMBL. Baseline patient features are listed
in (Supporting Information Table II). Median age was 60
years (range, 33–70) and 137 (57.1%) were male; roughly
one-third of cases showed elevated b2-microglobulin levels.
Seventy-nine patients (33.1%) were IGHV-UM, 45.8% were
ZAP-70-positive, and 19.2% CD38-positive. FISH data,
available in 226/240 cases, identified del(13q14) as the
most frequent abnormality followed by trisomy 12, while
there was a low incidence of del(11q22.3) cases and an
even lower percentage of del(17p13) cases.
Sixty-one out of 240 (25.4%) patients showed clinical
lymphadenopathies and/or organomegaly. Thirty-two
patients showed involvement of only one lymph node area,
13 of two lymph node areas, 2 of one lymph node area
and splenomegaly and 14 splenomegaly and/or hepatome-
galy. Thirty-one out of 240 cases (12.9%) showed head
and neck lymphadenopathies, 28 (11.7%) axillary lympha-
denopathies and 1 (0.4%) inguinal lymphadenopathy. Ten
cases (4.2%) had splenomegaly and 8 (3.3%) hepatome-
galy (Supporting Information Table II).
At TB-CT scan, 84/240 patients showed no organome-
galy or lymphadenopathies; head and neck lymph nodes
were enlarged in 62 cases (25.8%), axillary lymph nodes in
88 (36.7%), inguinal lymph nodes in 33 (13.8%), thoracic
lymph nodes in 22 (9.2%), and abdominal lymph nodes in
59 (24.6%). Lymphadenopathies had diameters between
15 and 30 mm. Moreover, 35 (14.6%) cases presented
splenomegaly, and 22 (9.2%) hepatomegaly (Supporting
Information Table II).
There was discordance between radiological and clinical
examination in 53/240 (22.1%) cases for head and neck
lymph node involvement; in 42 cases, TB-CT scans
revealed lymphadenopathies not seen at clinical assess-
ment, while in 11 cases lymphadenopathy was not con-
firmed radiologically (Table I). There was discordance for
axillary lymph node involvement in 70/240 (29.2%) patients;
TB-CT scans did not confirm lymphadenopathy in 5 cases,
while in 65 cases negative at clinical level radiological ex-
amination revealed lymphadenopathy. TB-CT scans dem-
onstrated inguinal lymphadenopathy not observed at
physical examination in 32/240 (13.3%) patients. There
were discrepancies regarding splenomegaly in 31 (12.9%)
cases; the TB-CT scans did not confirm the presence of
clinical splenomegaly in three cases, while they revealed
splenomegaly not identified on clinical examination in 28
cases. There was discordance regarding hepatomegaly in
24 (10%) cases; TB-CT scan identified 19 cases with hepa-
tomegaly undetected at clinical examination, and did not
confirm the presence of clinical hepatomegaly in 5 cases.
Restaging of patients: Binet A cases
Forty-eight out of 240 Binet A patients (20%) were con-
verted into r-Binet stage B. Among these reclassified
patients 64.6% were male, 35.9% showed elevated b2-
microglobulin level, 41.7% were IGHV-UM, 50% had a high
ZAP-70 expression, 27.1% were CD38-positive, and 15.9%
showed high-risk FISH lesions (Table II). r-Binet B patients
showed a statistically higher rate of high-risk cytogenetic
cases than r-Binet A patients (15.9% vs. 5.5%; P5 0.027).
The distribution of the remaining parameters were not stat-
istically significant (Table II).
After a median follow-up of 31 months, 56/230 (24.3%)
evaluable cases showed disease progression. r-Binet B
patients showed a significantly shorter PFS than those with
r-Binet A (2-year PFS probability, 71.2% vs. 87.4%;
P50.001) (Fig. 2). At Cox univariate analysis, r-Binet stage
[HR5 2.55, 95%CI (1.38–4.71); P50.003], CD38
[HR5 3.19, 95%CI (1.8–5.79); P<0.0001] and ZAP-70
expression [HR5 2.29, 95%CI (1.3–4.02); P50.004] and
IGHV mutational status [HR5 4.16, 95%CI (2.37–7.31);
P<0.0001] showed a statistically significant impact on PFS
(Table III). At Cox multivariate analysis, only r-Binet stage
[HR5 2.48, 95%CI (1.33–4.62); P50.004] and IGHV muta-
tional status [HR5 3.01, 95%CI (1.48–6.15); P5 0.002]
maintained an independent prognostic impact (Table III).
Moreover, 22 cases with thoracic lymphadenopathies
showed a nonstatistically different PFS as compared to 208
cases without pathologic thoracic lymph nodes (2-year PFS
probability, 76.5% vs. 85.8%, P5 0.16); while 59 cases with
abdominal lymphadenopathies had a significantly shorter
PFS than 161 cases with a normal abdominal CT scan (2-
year PFS probability, 74.4% vs. 88.2%, P<0.0001).
Finally, TB-CT scan allowed the early identification of a
second neoplasm in 2 cases (lung cancer and renal cell
carcinoma).
TABLE I. Discrepancies Between Radiological and Clinical Examination for Lymph Node Involvement and Organomegalies
No. of patients (%)
Clinical
examination
Radiological
examination Discordance
CT scan1/
Clinical grounds2
CT scan-/
Clinical grounds1
Head-neck adenopathy 31 (12.9) 62 (25.8) 53 (22.1) 42 (17.5) 11 (4.6)
Axillary adenoapathy 28 (11.7) 88 (36.7) 70 (29.2) 65 (27.1) 5 (2.1)
Inguinal adenopathy 1 (0.4) 33 (13.7) 32 (13.3) 32 (13.3) 0 (0)
Splenomegaly 10 (4.1) 35 (14.6) 31 (12.9) 28 (11.7) 3 (1.2)
Hepatomegaly 8 (3.3) 22 (9.2) 24 (10) 19 (7.9) 5 (2.1)
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Restaging of patients: Rai low-risk cases
There were 179 Rai low-risk and 61 Rai intermediate-risk
cases among Binet A patients. On the basis of CT scan
data, 100/179 (55.9%) low-risk patients were redefined as
r-Rai intermediate-risk. This subset of patients showed a
statistically higher rate of cases with higher ZAP-70 (52.5%
vs. 35.9%; P5 0.033) and CD38 expression (23% vs.
10.1%; P5 0.029) and b2-microglobulin levels (32.1% vs.
11.1%; P<0.0001) than r-Rai low-risk patients (Table II).
After a median follow-up of 30 months, 29/172 (16.9%)
evaluable cases showed disease progression. r-Rai inter-
mediate-risk patients had a significantly shorter PFS than
r-Rai low-risk patients (2-year PFS probability, 85% vs.
97.2%; P50.008) (Fig. 3). At Cox univariate analysis, r-Rai
stage [HR5 3.86, 95%CI (1.46–10.26); P50.007], b2-
microglobulin level [HR5 3.15, 95%CI (1.41–7.04);
P50.005], CD38 [HR5 4.14, 95%CI (1.87–9.14);
P50.001], ZAP-70 expression [HR5 2.57, 95%CI (1.16–
5.68); P50.02] and IGHV mutational status [HR5 5.43,
95%CI (2.42–12.2); P< 0.0001] showed a statistically
significant impact on PFS (Table III). At Cox multivariate
analysis, only r-Rai stage [HR5 2.78, 95%CI (1.02–7.59);
P5 0.046] and IGHV mutational status [HR5 4.25, 95%CI
(1.43–12.6); P5 0.009] maintained an independent prog-
nostic impact (Table III).
Furthermore, thoracic CT scans failed to significantly
separate the clinical outcome of those 13 cases with tho-
racic lymphadenopathies from 159 radiologically negative
cases (2-year PFS probability, 90.4% vs. 90.9%, P50.2),
while 34 cases with abdominal lymphadenopathies showed
a statistically shorter PFS than 138 cases without patholog-
ical abdominal lymph nodes (2-years PFS probability,
82.5% vs. 92.3%, P< 0.0001).
Restaging of patients: cMBL cases
On the basis of TB-CT scan data, 29/69 (42%) cMBL
patients were redefined as r-SLLs. Of note, no statistically
different distribution of clinical and biological parameters
was observed between r-cMBL and r-SLL patients (Table
II). After a median follow-up of 35 months, 5/66 cases
evaluable presented progression (3 r-cMBLs and 2 r-SLLs).
Considering all clinical Rai low-risk patients, no statistical
difference in PFS was observed between those reclassified
as r-cMBL, r-SLL, or r-Rai low-risk patients, while r-Rai in-
termediate-risk cases showed a statistically shorter PFS
(2-years PFS probability, r-cMBL 97%, r-SLL 92.3%, r-Rai
low-risk 97.2%, r-Rai intermediate-risk 81.9%, P< 0.0001).
Discussion
CT scan is not routinely recommended for CLL patient
work-up in contrast with other low-grade lymphoproliferative
disorders [20]. Moreover, the studies investigating the clini-
cal significance of TB-CT scan in CLL are scanty.
Herein, we investigated whether early stage CLL can be
upstaged using TB-CT scan and whether these upstaged
patients have clinical and biological characteristics and
PFS (determined by need for therapy) differing from those
who are not upstaged. A similar evaluation was performed
in cMBL patients. This category of patients was included in
the O-CLL1 protocol when enrollment began in 2006 since
the investigators followed the 1996 NCI/WG guidelines for
CLL diagnosis [7]. cMBL was later recognized as a sepa-
rate entity by 2008 NCI/WG guidelines [8]. Finally, we eval-
uated the prognostic impact of thoracic and abdominal
lymphadenopathies.
In our series, 25% of 240 Binet A patients presented
clinical lymphadenopathy and/or organomegaly; this per-
centage reached 65% following TB-CT scan, mainly due to
the identification of thoracic and abdominal lymphadenopa-
thies in 9% and in 24% of the cases, respectively. Studies
Figure 2. PFS according r-Binet stage. Taking into consideration only radiologi-
cal data 48/240 Binet A patients (20%) were converted into r-Binet stage B. r-
Binet B patients showed a significantly shorter time to progression than those with
r-Binet A (2-year PFS probability, 71.2% vs. 87.4%; P5 0.001).
TABLE II. Correlation Among Main Initial Characteristics and Staging Systems Integrated with TB-CT Scan
Clinical staging
Binet stage A (n5 240)
P
Rai low-risk stage (n5 179)
P
cMBL (n569)
PRadiological staging
% of Binet
stage
A pts
(n5192)
% of Binet
stage B
pts (n5 48)
% of Rai low-
risk stage
pts (n5 79)
% of Rai
intermediate-
risk stage
pts (n5 100)
% of
cMBL pts
(n540)
% of SLL
pts (n529)
Sex Male/Female 55.2/44.8 64.6/35.4 ns 46.8/53.2 60/40 ns 47.5/52.5 51.7/48.3 ns
Age <60/>60 yr 46.4/53.6 56.3/43.7 ns 45.6/54.4 49/51 ns 45/55 37.9/62.1 ns
Lymphocyte count <30/>30 3 109/l 90.6/9.4 93.8/6.2 ns 97.5/2.5 90/10 ns – – –
b2-microglobulin (n5203) normal/elevated 75/25 64.1/35.9 ns 88.9/11.1 61.8/32.2 <0.0001 83.9/16.1 62.5/37.5 ns
LDH (n5 216) normal/elevated 92.5/7.5 95.3/4.7 ns 95.6/4.4 91.6/8.4 ns 91.7/8.3 92.6/7.4 ns
CD38 expression negative/positive 82.8/17.2 72.9/27.1 ns 89.9/10.1 77/23 0.029 90/10 75.9/24.1 ns
ZAP-70 expression (n5 238)
negative/positive
55.3/44.7 50/50 ns 64.1/35.9 47.5/52.5 0.033 62.5/37.5 44.8/55.2 ns
IGHV mutational status (n5239)
mutated/germline
69.1/30.9 58.3/41.7 ns 74.4/25.6 66/34 ns 82.1/17.9 62.1/37.9 ns
Cytogenetic risk (n5 226)
low1 intermediate/high
94.5/5.5 84.1/15.9 0.027 94.4/5.6 92.9/7.1 ns 97.1/2.9 92.9/7.1 ns
ns, not significant.
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investigating thoracic lymph node involvement in a large
cohort of CLLs are unavailable, although thoracic lympha-
denopathies are traditionally considered infrequent [21]. We
found a more common involvement of abdominal lymph
nodes at a rate comparable with that reported by Munta-
nola et al., who demonstrated abdominal lymphadenopa-
thies in 27% of 140 Rai 0 cases by CT scans [11].
Moreover, we observed an important discrepancy between
radiological and clinical examinations concerning superficial
lymphadenopathies (see Table II), possibly due to the rela-
tively small lymph node diameter in numerous patients.
Moreover, spleno-/hepatomegaly were more easily
detected radiologically. Together the findings indicate a
greater sensitivity of the imaging techniques. Does this
greater sensitivity translate into clinically relevant informa-
tion? Indeed, PFS was shorter for r-Binet B than for r-Binet
A patients. Interestingly, multivariate analysis demonstrated
that IGHV mutational status and r-Binet stage were the
only two variables independently associated with progres-
sion. In connection with this it is of note that r-Binet B
patients also showed a higher rate of high-risk cytogenet-
ics. These data are in line with the reported frequent asso-
ciation between lymphadenopathies and certain high-risk
cytogenetic alterations such as del11q [22,23]. Importantly,
our study revealed that the presence of abdominal lympha-
denopathies negatively impacted on PFS. The low number
of cases presenting thoracic lymphadenopathies precluded
a statistically sound evaluation.
Binet A patients were subclassified into Rai low- and in-
termediate-risk cases. About 56% of low-risk patients
showed lymphadenopathy and/or organomegaly using TB-
CT scans and could be classified as r-Rai intermediate-risk
patients. The latter comprised a significantly higher rate of
cases with high CD38 and ZAP-70 expression and elevated
b2-microglobulin levels. The higher b2-microglobulin levels
likely reflects the CLL tumor burden [24]. Moreover, within
the clinical Rai low-risk group, those reclassified as r-Rai
intermediate-risk had a significantly shorter PFS. Also,
r-Rai stage and IGHV mutational status remained inde-
pendently associated with progression reaffirming the value
of radiological data. Again in this subgroup the presence of
abdominal lymphadenopathies was a predictor of progres-
sion, confirming data by Muntanola et al. [11].T
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Figure 3. PFS according r-Rai stage in clinical Rai stage 0 patients. Based
upon CT scan data, 100/179 (55.9%) Rai low-risk patients were redefined as r-Rai
intermediate-risk. r-Rai intermediate-risk patients had a significant shorter time to
progression than those with r-Rai low-risk (2-year PFS probability, 85% vs. 97.2%;
P5 0.008).
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We observed a high rate of cases (more than 40%) with
lymphadenopathy and/or organomegaly at TB-CT scan
within the cMBL group; these patients should not be con-
sidered as having true cMBL but SLL according to IWCLL
guidelines [8]. In fact, the definition of SLL requires the
presence of lymphadenopathy and/or splenomegaly (as
defined by physical examination or CT scan) associated
with <5.0 3 109/l lymphocytes fulfilling the phenotypic fea-
tures of CLL/SLL [8]. Likewise, the presence of lymphade-
nopathy and/or splenomegaly represent exclusion criteria
for cMBL [8]. Accordingly, Rossi et al. reported that 15% of
cMBLs progressed to SLLs, suggesting that some cMBLs
are SLLs with a very low tumor burden at diagnosis [25].
Scarfo et al. found lymphadenopathy and/or hepato-/sple-
ganomegaly in only 6% of cMBL by radiologic evaluation,
although the criteria utilized for defining lymphadenopathies
were not clearly outlined in the study [26]. Overall, our and
other data support the notion that TB-CT scan could cor-
rectly distinguish between cMBLs and SLLs. Unfortunately,
the relatively low number of cases and events in our series
does not allow to definitively establish whether r-cMBLs
and r-SLLs have a different prognosis.
Finally, TB-CT scan allowed the early diagnosis of a con-
comitant neoplasm in 2 cases. It is known that patients
with CLL have a high risk of developing a second cancer
and an increased frequency of certain cancer types [27].
Nonetheless, there are no studies investigating the use of
TB-CT scans in routine screening or follow-up to preco-
ciously detect cancer in CLL.
Overall, these results indicate that TB-CT scan, through
a more accurate evaluation of tumor burden than clinical
examination, allows the identification of a subset of cases
with a more aggressive disease in early stage CLL
patients. Moreover, in patients with <5.0 3 109 B lympho-
cytes/l, TB-CT scan can differentiate between true cMBL
and SLL cases. On the basis of our results it may be pre-
mature to recommend the routine use of TB-CT scan in all
early stage CLL patients, as this recommendation should
also consider obvious economic constraints. Nevertheless,
our data provide groundwork for performing a larger study
to verify the prognostic significance of TB-CT scan along
with other new prognostic parameters in CLL patients.
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